Wednesday, 16 August 2017

Zydus Cadila bags approval for Tiadylt ER capsules

Commodity Tips

GET INDIAN STOCK MARKET FREE STOCK MARKET FROM HERE >> http://www.ripplesadvisory.com/free-trial.php

Zydus Cadila has said that it has received the USFDA final approval to market Tiadylt ER (Diltiazem Hydrochloride Extended-Release, USP) capsules (in strengths of 120 mg, 180 mg, 240 mg, 300 mg, 360 mg and 420 mg) and Azelastine Hydrochloride Nasal Spray (137 mcg). “Tiadylt ER capsules are used to treat hypertension, angina and certain heart rhythm disorders. The drug will be manufactured at the group’s formulations manufacturing facility at Ahmedabad,” the company said in a filing to the Bombay Stock Exchange.

On the other hand, Azelastine Hydrochloride is used to relieve nasal symptoms such as runny/itching/stuffy nose, sneezing and post-nasal drip caused by allergies or other conditions. It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad. The group now has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY03-04. Meanwhile, shares of the company were trading at Rs 477.60 apiece, down 1.55 per cent from the previous close at 14:10 hours on BSE.

No comments:

Post a Comment

Note: only a member of this blog may post a comment.